MOTS-c is moving into its key administered-human test: 120 adults, 12 weeks, subcutaneous dosing, and OGTT-derived insulin sensitivity as the primary endpoint. Body weight and waist circumference are secondary outcomes. That hierarchy tells you exactly how to read the result when it posts.
Comparison at a glance
| Option | Best reason to consider it | Routine | Most relevant evidence | Verdict |
|---|---|---|---|---|
| MOTS-c injection | Direct match to the Phase 2 research question | Product guide covers concentration, schedule, supply, storage, and price | Recruiting 120-person, 12-week subcutaneous placebo-controlled trial | Insulin-sensitivity research lead |
| NAD+ formats | Direct NAD+ and cellular-energy intent | Current injection, nasal, and sublingual options | NAD+ metabolism and route choice | Different category |
| Methylcobalamin B12 injection | Testing shows low B12 | 5 mg/mL, 10 mL, 60 days, $44.50 first month, then $89/month | Deficiency treatment | Does not answer the MOTS-c trial question |
MOTS-c owns the research question. The recruiting trial will supply the first substantial controlled administered-human result for insulin sensitivity in this population.
The decisive distinction
The trial design determines what its eventual results can mean: who is enrolled, what route is used, how long treatment lasts, and which endpoint is primary.
What MOTS-c is
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA and detected in human skeletal muscle and circulation. Rebody's intended MOTS-c format is an injection vial. This identity keeps similar names, salts, precursors, endogenous physiology, and finished products from being compared as though they were one molecule.
Keep every result attached to its molecule and route. Endogenous MOTS-c after exercise, administered mouse results, subcutaneous Phase 2 treatment, NAD+ formats, and B12 deficiency each answer different questions.
What the strongest evidence measured
In 10 young men, a stationary-bike session increased the body's own MOTS-c in skeletal muscle and serum. Administered MOTS-c improved physical-capacity or metabolic measures in mice. A recruiting Phase 2a trial now plans 120 adults with prediabetes and overweight or obesity, 12 weeks of subcutaneous MOTS-c or placebo, and an OGTT-derived insulin-sensitivity endpoint.
For MOTS-c, NAD+, and B12, the molecule, route, study population, duration, and measured endpoint define the claim. Route, storage, schedule, supply, and price decide whether the best-matched option is practical.
Read the Phase 2 design before predicting the result
The planned Phase 2a study enrolls 120 adults with prediabetes and overweight or obesity. It uses subcutaneous MOTS-c or placebo for 12 weeks, then follows safety for four more weeks. An oral-glucose-tolerance-test-derived insulin-sensitivity measure is central to the design; body weight and waist circumference are secondary rather than the sole point of the trial.
That population matters. A result in adults with prediabetes cannot automatically become an athletic-performance claim for metabolically healthy people. The route matters too: a subcutaneous trial does not validate an oral, nasal, or different injectable formulation. Twelve weeks establishes the observation window, not a universal protocol.
Until results post, “before and after” claims have no controlled human treatment dataset behind them. The study can still be described strongly: it is the key test of whether administered MOTS-c changes insulin sensitivity in people under a defined protocol. Pending is a factual trial status, not a reason to bury the research question.
The clean checkpoint after publication will be the prespecified endpoint, between-group result, confidence interval, adverse-event pattern, and completion rate—not a promotional summary or selected responder. Secondary weight and waist findings should stay secondary unless the study was powered and interpreted to support more.
Baseline characteristics will matter as much as the headline. Age, starting glucose control, body composition, concomitant medications, and adherence determine how broadly the result travels. A meaningful average insulin-sensitivity change could coexist with no important weight difference, and the reverse could also occur. Read each endpoint on its own terms rather than compressing the trial into “worked” or “failed.” The placebo difference and adverse-event withdrawals matter more than isolated before-and-after responders. Completion rate and missing data will shape confidence in the final estimate and its practical size as well. The full results table matters.
The Phase 2 trial is the decision point
MOTS-c is the direct insulin-sensitivity research candidate. Phase 2 uses the exact design the question needs: administered peptide, placebo control, a metabolically selected human population, and a prespecified insulin-sensitivity endpoint.
The MOTS-c case depends on administered MOTS-c evidence. Endogenous exercise data, NAD+ biology, and B12 deficiency treatment answer different questions and cannot supply a Phase 2 result before one is posted.
Read the trial in the order it was designed
The primary endpoint is change in OGTT-derived insulin sensitivity after 12 weeks. That is the result that should lead any future update. Body weight and waist circumference are secondary endpoints. Safety assessments include adverse events, laboratory measures, vital signs, and ECG information.
If a future headline leads with pounds lost while hiding the insulin-sensitivity result, it is not representing the study’s hierarchy honestly.
The strongest update will put the between-group insulin-sensitivity change first, followed by its confidence interval and completion rate. Weight and waist can then show whether metabolic movement traveled with a visible body-composition change. That order gives a positive, negative, or mixed result the same disciplined reading.
Who the trial can answer for
The planned population is 120 adults with prediabetes and overweight or obesity. A result in that population would not automatically apply to trained athletes, adults with normal glucose regulation, people seeking cognitive benefits, or every older adult interested in longevity.
The route is subcutaneous administration, and the treatment period is 12 weeks with safety follow-up. Those facts define the experiment; they do not define Rebody’s future formulation or dosage.
What would count as a meaningful result
A reported between-group change, uncertainty interval, adverse-event pattern, completion rate, and prespecified analysis matter more than a press-release adjective. Baseline balance, missing data, and whether the result holds across sensitivity analyses will matter too.
A positive primary endpoint would support an administered-human metabolic claim within the trial’s scope. It still would not establish exercise replacement, lifespan extension, or universal weight loss.
A positive result would still have boundaries
Suppose the trial meets its primary endpoint. The defensible conclusion would be that the tested subcutaneous MOTS-c regimen improved the prespecified OGTT-derived insulin-sensitivity measure versus placebo over 12 weeks in the enrolled population. It would not automatically prove diabetes prevention, durable weight loss, improved athletic performance, or benefit for metabolically healthy adults.
Next inspect the effect size, confidence interval, completion rate, missing data, adverse events, and whether secondary weight or glucose findings agree with the primary analysis. Subgroup signals should remain exploratory unless the trial was designed and powered for them. A negative primary result also cannot be rescued by selecting an attractive secondary endpoint after the fact. This order keeps a real Phase 2 result from becoming a claim the protocol never tested.
Questions about the MOTS-c Phase 2 trial
Has the trial reported results?
The trial is recruiting, and outcome results are still pending. The next meaningful update is the posted primary-endpoint analysis.
Why use an oral glucose tolerance test?
An OGTT measures the response to a defined glucose load. The derived insulin-sensitivity endpoint answers a more specific metabolic question than a fasting snapshot or consumer glucose trace.
Is weight loss the primary endpoint?
OGTT-derived insulin sensitivity is primary. Body weight and waist circumference are secondary outcomes.
Does enrollment mean MOTS-c treats prediabetes?
No. A trial population defines who is being studied; it does not create an approved indication or positive result.
When will Rebody publish a MOTS-c dose and price?
Only when the finished offer is ready. Chemical form, concentration, vial size, delivered amount, schedule, supply, storage, shipping, price, and states remain unpublished.
Can athletes use MOTS-c while waiting for results?
MOTS-c is prohibited under the 2026 WADA list. Trial status and commercial availability do not change that rule.
Where current products fit
B12 remains the cause-specific answer when deficiency is documented and costs $44.50 first month, then $89/month. NAD+ remains a separate direct-coenzyme category with injection at $189 for the first two-month shipment, then $249 every two months ($124.50/month equivalent); the current 12 mL nasal spray at $59.50 first month, then $119/month; and sublingual tablets at $99.50 first month, then $199/month.
Neither category answers the MOTS-c trial question. Their availability is useful for shoppers, not a substitute endpoint.
What we can say before the result
The strongest current article can say exactly why the trial matters without guessing the result: it is randomized, administered-human, subcutaneous, 12 weeks, metabolically selected, and centered on insulin sensitivity. That is already a major step beyond mouse obesity findings and endogenous exercise physiology.
Decisive bottom line
MOTS-c is the leading insulin-sensitivity unregulated peptide product in this set because a properly scoped human trial is underway. Read the OGTT-derived primary endpoint first, then weight, waist, tolerability, and completion. WADA prohibits MOTS-c in tested sport.
Keep reading
- Body-Composition Peptides for Muscle and Fat Metabolism
- Peptides for Insulin Sensitivity and Glucose Metabolism
- Peptides for Metabolic Health After 40